Overview

Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer

Status:
Unknown status

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

RATIONALE: Imaging procedures, such as fludeoxyglucose F18 positron emission tomography (^18FDG-PET), may improve the ability to detect disease progression and help doctors predict a patient's response to treatment and plan more effective treatment. PURPOSE: This phase II trial is studying how well ^18FDG-PET imaging works in detecting disease progression and determining response to treatment in patients who are undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.

Phase:

Phase 2

Details

Lead Sponsor:

American College of Radiology Imaging Network

Collaborators:

National Cancer Institute (NCI)
Radiation Therapy Oncology Group

Treatments:

Carboplatin
Docetaxel
Etoposide
Fluorodeoxyglucose F18
Paclitaxel
Vinblastine
Vinorelbine